Effects of Virtual Reality-Based Optokinetic Stimulation Added to Neuromuscular Training in Basketball Players
NCT07918599, Not applicable, Recruiting, Bahçeşehir University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of Virtual Reality-Based Optokinetic Stimulation Added to Neuromuscular Training in Basketball Players | ClinicalTrials.gov |
| NCT number | NCT07918599 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 42 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Bahçeşehir University | ClinicalTrials.gov |
| Conditions | Visual Dependence, Postural Control, Jump-Landing Biomechanics | ClinicalTrials.gov |
| Interventions | Neuromuscular Training, Virtual Reality-Based Optokinetic Stimulation | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Peak Knee Flexion Angle During Drop Vertical Jump Landing | Baseline and immediately after the six-week intervention | Peak knee flexion angle of the dominant limb will be measured in degrees using the Xsens MVN Awinda inertial motion capture system during a standardized drop vertical jump from a 30-cm box. The peak angle will be identified during the landing deceleration phase, from initial ground contact to maximum knee flexion. Initial contact will be determined using synchronized force-platform data. The dominant limb will be defined as the preferred leg for kicking a ball. Three successful trials will be recorded at each assessment. Change from baseline to the end of the six-week intervention will be evaluated. | ClinicalTrials.gov |
| Secondary | Change in Peak Vertical Ground Reaction Force During Drop Vertical Jump Landing | Baseline and immediately after the six-week intervention | Peak vertical ground reaction force will be measured using a Bertec force platform sampling at 1000 Hz during the standardized drop vertical jump. Initial contact will be defined as the first instant at which filtered vertical ground reaction force exceeds 10 N. Peak force will be identified as the maximum vertical ground reaction force within the first 0.20 seconds after initial contact and normalized to body weight, expressed in multiples of body weight. Three successful trials will be recorded at each assessment. Change from baseline to the end of the six-week intervention will be evaluated. | ClinicalTrials.gov |
| Secondary | Change in Time to Peak Vertical Ground Reaction Force During Drop Vertical Jump Landing | Baseline and immediately after the six-week intervention | The time interval between initial ground contact and peak vertical ground reaction force will be measured in seconds using a Bertec force platform sampling at 1000 Hz during the standardized drop vertical jump. Initial contact will be defined as the first instant at which filtered vertical ground reaction force exceeds 10 N. Peak vertical ground reaction force will be identified within the first 0.20 seconds after initial contact. Three successful trials will be recorded at each assessment. Change from baseline to the end of the six-week intervention will be evaluated. | ClinicalTrials.gov |
| Secondary | Change in Landing Load Absorption Duration During Drop Vertical Jump Landing | Baseline and immediately after the six-week intervention | Landing load absorption duration will be measured in seconds as the time interval between peak vertical ground reaction force and maximum knee flexion of the dominant limb during the standardized drop vertical jump. Peak vertical ground reaction force will be identified within the first 0.20 seconds after initial contact using a Bertec force platform. Maximum knee flexion will be identified using synchronized Xsens MVN Awinda motion capture data. The dominant limb will be defined as the preferred leg for kicking a ball. Three successful trials will be recorded at each assessment. Change from baseline to the end of the six-week intervention will be evaluated. | ClinicalTrials.gov |
| Secondary | Change in Hip Flexion Range of Motion During Drop Vertical Jump Landing | Baseline and immediately after the six-week intervention | Hip flexion range of motion will be measured in degrees using the Xsens MVN Awinda system, from initial ground contact to the instant of maximum dominant-knee flexion during the standardized drop vertical jump. Bilateral measurements will be calculated within the same analysis window. | ClinicalTrials.gov |
| Secondary | Change in Knee Flexion Range of Motion During Drop Vertical Jump Landing | Baseline and immediately after the six-week intervention | Knee flexion range of motion will be measured in degrees using the Xsens MVN Awinda system, from initial ground contact to the instant of maximum dominant-knee flexion during the standardized drop vertical jump. Bilateral measurements will be calculated within the same analysis window. | ClinicalTrials.gov |
| Secondary | Change in Ankle Dorsiflexion Range of Motion During Drop Vertical Jump Landing | Baseline and immediately after the six-week intervention | Ankle dorsiflexion range of motion will be measured in degrees using the Xsens MVN Awinda system, from initial ground contact to the instant of maximum dominant-knee flexion during the standardized drop vertical jump. Bilateral measurements will be calculated within the same analysis window. | ClinicalTrials.gov |
| Secondary | Change in Time to Peak Knee Flexion During Drop Vertical Jump Landing | Baseline and immediately after the six-week intervention | The interval from initial ground contact to maximum knee flexion of the dominant limb will be measured in seconds using synchronized Bertec force-platform and Xsens MVN Awinda data during the standardized drop vertical jump. | ClinicalTrials.gov |
| Secondary | Change in Peak Knee Valgus Angle During Drop Vertical Jump Landing | Baseline and immediately after the six-week intervention | Peak dominant-knee valgus angle will be measured in degrees using the Xsens MVN Awinda system during the interval from peak vertical ground reaction force to maximum dominant-knee flexion. Valgus will be defined as the maximum positive value of the dominant-knee abduction/adduction angle. | ClinicalTrials.gov |
| Secondary | Change in Peak Resultant Tibial Acceleration During Drop Vertical Jump Landing | Baseline and immediately after the six-week intervention | Peak resultant tibial acceleration will be calculated from the three-axis free-acceleration signals of the lower-leg sensors of the Xsens MVN Awinda system during landing load absorption, defined as the interval from peak vertical ground reaction force to maximum dominant-knee flexion. Acceleration will be expressed in meters per second squared. | ClinicalTrials.gov |
| Secondary | Change in Romberg Sway Area Ratio | Baseline and immediately after the six-week intervention | Visual dependence will be assessed using the ratio of eyes-closed to eyes-open center-of-pressure sway area measured with a Bertec force platform during tandem stance. Two 30-second trials will be performed under each condition. The ratio is dimensionless, with higher values indicating greater reliance on vision for postural control. | ClinicalTrials.gov |
| Secondary | Change in Romberg Sway Velocity Ratio | Baseline and immediately after the six-week intervention | Visual dependence will be assessed using the ratio of eyes-closed to eyes-open mean center-of-pressure velocity measured with a Bertec force platform during tandem stance. Two 30-second trials will be performed under each condition. The ratio is dimensionless, with higher values indicating greater reliance on vision for postural control. | ClinicalTrials.gov |
| Secondary | Change in Center-of-Pressure Sway Area During Tandem Stance | Baseline and immediately after the six-week intervention | Center-of-pressure sway area will be measured using a Bertec force platform during tandem stance with eyes open and eyes closed. Two 30-second trials will be performed under each condition. Results will be reported separately for each visual condition in square centimeters. | ClinicalTrials.gov |
| Secondary | Change in Center-of-Pressure Total Path Length During Tandem Stance | Baseline and immediately after the six-week intervention | Total center-of-pressure path length will be measured using a Bertec force platform during tandem stance with eyes open and eyes closed. Two 30-second trials will be performed under each condition. Results will be reported separately for each visual condition in centimeters. | ClinicalTrials.gov |
| Secondary | Change in Mean Center-of-Pressure Velocity During Tandem Stance | Baseline and immediately after the six-week intervention | Mean center-of-pressure velocity will be measured using a Bertec force platform during tandem stance with eyes open and eyes closed. Two 30-second trials will be performed under each condition. Results will be reported separately for each visual condition in centimeters per second. | ClinicalTrials.gov |
| Secondary | Change in Peak Anterior-Posterior Center-of-Mass Velocity During Drop Vertical Jump Landing | Baseline and immediately after the six-week intervention | Peak anterior-posterior center-of-mass velocity will be obtained from Xsens MVN Awinda data during landing load absorption, defined as the interval from peak vertical ground reaction force to maximum dominant-knee flexion. Velocity will be expressed in meters per second. | ClinicalTrials.gov |
| Secondary | Change in Peak Medial-Lateral Center-of-Mass Velocity During Drop Vertical Jump Landing | Baseline and immediately after the six-week intervention | Peak medial-lateral center-of-mass velocity will be obtained from Xsens MVN Awinda data during landing load absorption, defined as the interval from peak vertical ground reaction force to maximum dominant-knee flexion. Velocity will be expressed in meters per second. | ClinicalTrials.gov |
| Secondary | Change in Peak Vertical Center-of-Mass Velocity During Drop Vertical Jump Landing | Baseline and immediately after the six-week intervention | Peak vertical center-of-mass velocity will be obtained from Xsens MVN Awinda data during landing load absorption, defined as the interval from peak vertical ground reaction force to maximum dominant-knee flexion. Velocity will be expressed in meters per second. | ClinicalTrials.gov |
| Secondary | Change in Peak Anterior-Posterior Center-of-Mass Acceleration During Drop Vertical Jump Landing | Baseline and immediately after the six-week intervention | Peak anterior-posterior center-of-mass acceleration will be obtained from Xsens MVN Awinda data during landing load absorption, defined as the interval from peak vertical ground reaction force to maximum dominant-knee flexion. Acceleration will be expressed in meters per second squared. | ClinicalTrials.gov |
| Secondary | Change in Peak Medial-Lateral Center-of-Mass Acceleration During Drop Vertical Jump Landing | Baseline and immediately after the six-week intervention | Peak medial-lateral center-of-mass acceleration will be obtained from Xsens MVN Awinda data during landing load absorption, defined as the interval from peak vertical ground reaction force to maximum dominant-knee flexion. Acceleration will be expressed in meters per second squared. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)